ETON Eton Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ETON

Price (delayed)

$42.59

Market cap

$1.17B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.05

Enterprise value

$1.18B

?
Relative Growth: Rel. Growth: 93
Relative Strength: Rel. Strength: 98
Relative Valuation: Rel. Valuation: 9
Relative Profitability: Rel. Profitability: 54

Eton Pharmaceuticals, Inc. is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The company currently owns or receives royalties from three FDA-approved products, including ALKINDI® ...

Highlights
The revenue has soared by 76% YoY and by 8% QoQ
ETON's EPS has surged by 74% year-on-year and by 71% since the previous quarter
The quick ratio has contracted by 44% YoY and by 23% from the previous quarter
The gross margin has contracted by 8% YoY
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://etonpharma.com
Peers: OPK ORGO

Key stats

What are the main financial stats of ETON

ETON stock price

How has the Eton Pharmaceuticals stock price performed over time
Intraday
-3.51%
1 week
0.64%
1 month
25.34%
1 year
177.1%
YTD
151.86%
QTD
17.65%

Financial performance

How have Eton Pharmaceuticals's revenue and profit performed over time
Revenue
$86.93M
Gross profit
$47.61M
Operating income
$2.04M
Net income
-$1.48M
Gross margin
54.8%
Net margin
-1.7%
The company's operating margin has surged by 196% YoY
The net margin has surged by 82% year-on-year and by 70% since the previous quarter
The revenue has soared by 76% YoY and by 8% QoQ
The company's net income has surged by 68% QoQ and by 68% YoY

Price vs fundamentals

How does ETON's price correlate with its fundamentals

Growth

What is Eton Pharmaceuticals's growth rate over time

Valuation

What is Eton Pharmaceuticals stock price valuation
P/E
N/A
P/B
37.96
P/S
13.37
EV/EBIT
577.53
EV/EBITDA
188.87
EV/Sales
13.55
ETON's EPS has surged by 74% year-on-year and by 71% since the previous quarter
The stock's price to book (P/B) is 89% more than its last 4 quarters average of 20.1
ETON's equity is up by 25% year-on-year and by 17% since the previous quarter
ETON's P/S is 162% above its 5-year quarterly average of 5.1 and 91% above its last 4 quarters average of 7.0
The revenue has soared by 76% YoY and by 8% QoQ

Efficiency

How efficient is Eton Pharmaceuticals business performance
Eton Pharmaceuticals's ROIC has soared by 152% YoY
ETON's return on sales has surged by 150% year-on-year
The return on assets has surged by 81% year-on-year and by 69% since the previous quarter
Eton Pharmaceuticals's ROE has soared by 76% YoY and by 70% from the previous quarter

Dividends

What is ETON's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ETON.

Financial health

How did Eton Pharmaceuticals financials performed over time
ETON's total assets is 46% more than its total liabilities
The quick ratio has contracted by 44% YoY and by 23% from the previous quarter
Eton Pharmaceuticals's current ratio has decreased by 39% YoY and by 23% from the previous quarter
ETON's equity is up by 25% year-on-year and by 17% since the previous quarter
ETON's debt to equity is down by 17% year-on-year and by 14% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.